Dimicarb

Therapeutic indications:

Veterinary drug DIMICARB is indicated for cattle, sheep, horses and dogs for prevention and treatment of parasitic diseases, caused by blood parasites: babesiosis, nuttalliosis, anaplasmosis, piroplasmosis and mixed invasions.

Composition of the veterinary drug:

1 ml DIMICARB solution for injection contains:

• Imidocarb dipropionate 120 mg
• Cyanocobalamin (vitamin B12) 0.2 mg as an active substances;

Pharmacological activity:

Active substances of the veterinary drug are imidocarb dipropionate and cyanocobalamin (vitamin B12).

Imidocarb has antiparasitic activity against Babesia bovis, Babesia ovis, Piroplasma bigeminum, Babesia divergens, Piroplasma canis, Piroplasma caballi, Babesia gibsoni, Francaiella colchica, Theileria annulata, Theileria equi, Theileria sergenti, Theileria mutans, Theileria orientalis, Theileria ovis, Theileria recondita, Theileria tarandirangiferis, Nuttallia equi, Anaplasma marginale, Anaplasma ovis, and also Ehrlichia canis.

Imidocarb suppresses the intake of inositol, which is vitaly necessary for blood parasite, as well as hampers the production and metabolism of polyamines by parasites. After parenteral administration of the veterinary drug, imidocarb reaches its therapeutic concentration in blood in 18-24 hours. This concentration is maintained at the same level for 4-6 weeks. Imidocarb accumulates mainly in kidneys and liver, and is excreted mainly with urine.

Cyanocobalamin is a growth factor that is necessary for normal hematopoiesis and maturation of red blood cells. Cyanocobalamin is involved in the synthesis of choline, methionine, creatine and nucleic acids.

Dosage:

The veterinary drug is administered in compliance with the rules of aseptic and antiseptic, in the neck, by subcutaneous or intramuscular injection, in the following doses:

Precautions and adverse reactions:

In recommended doses, the veterinary drug doesn’t usually cause side effects and complications. In rare cases, a local reaction such as hyperemia or painful swelling at the injection site may occur; it disappears spontaneously within 1-2 days.

By the mass death of blood parasites and the destruction of red blood cells after the use of the veterinary drug in animals, intoxication may occur. In case of its occurrence, intensive therapy is prescribed, including intravenous administration of solutions of electrolytes and hepatoprotectors.

Use antihistamines in animals with clinical signs of babesiosis before administration of the veterinary drug.

Do not use in animals which are known to be hypersensitive to substances of the veterinary drug.

Do not use in animals within 4 weeks after vaccination with a live vaccine against babesiosis or anaplasmosis, and also in emaciated animals.

In case of the overdose and/or animal’s hypersensitivity to the veterinary drug, bradycardia, tachypnea and disordered breathing, anorexia, excessive salivation, sweating, muscle tremors, frequent urination and bowel movements may occur. Treatment should be symptomatic.

After the first administration and cancellation no peculiarities are revealed.

Do not use simultaneously with organochlorine, organophosphorus preparations and other cholinesterase inhibitors.

Do not use the veterinary drug in sheep whose milk is used for human consumption.

Withdrawal period:

Cattle, horses and sheep must not be slaughtered for human consumption within 28 days after the last treatment. Meat of animals forcibly slaughtered earlier than the specified period may be used for feeding fur animals.  Milk from lactating cows and mares may only be taken after 4 days from the last treatment for human consumption. Milk of animals, which is taken earlier than the specified period, may be used for feeding animals after boiling.

Storage conditions:

Store in a dry, dark place at a temperature of +2C to +25C. Keep out of reach of children.

Shelf-life:

Shelf-life of the veterinary drug under appropriate storage conditions is 18 months from the date of manufacture. Shelf-life after first opening: 28 days.